Clinical trials: Juvenile-Onset Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
Low Dose Cyclosporin and Methotrexate Therapy in Diabetes
The purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus
- Trial name
- NCT00905073
- Testing
- cyclosporin and methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Georgetown University
Diabetes Mellitus, Type 1
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
Ninety percent of patients with type-1-diabetes will develop late-diabetic complications in the eyes, kidneys, nervous- or cardiovascular-system.
- Trial name
- NCT00118937
- Testing
- Metformin
- Volunteers
- 100 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as…
- Trial name
- SWITCH 1 (NCT02034513)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 99 sites in United States, Poland and 1 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Retinal Ischemia, Diabetes Complications
Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning in Patients With Type 1 Diabetes
Remote ischemic conditioning (RIC) is a therapeutic strategy for protecting organs or tissue against the detrimental effects of acute ischemia-reperfusion injury.
- Conditions
- Retinal Ischemia, Diabetes Complications, Ischemia, Diabetes Mellitus, Type 1
- Trial name
- NCT03906383
- Testing
- Remote Ischemic Conditioning
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- University of Aarhus
Diabetes Mellitus, Type 1
Mindfulness-based Arabic Guided Self-help for Parents of Children With Type 1 Diabetes
Kuwait ranks as the third country worldwide for the incidence of type 1 diabetes (T1D) with an incidence of 37.10 per 100,000 children.
- Trial name
- NCT03358394
- Testing
- A human-interventional study
- Where
- Kuwait
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- SHAHAH ALTAMMAR
Type 1 Diabetes Mellitus
Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?
To see if using medication called sulphonylureas can help improve symptoms which patients rely on to recognise low blood glucose levels ( hypoglycaemia) and also to see if they can reduce the slowing down in brain function which…
- Trial name
- NCT00472875
- Testing
- Glibenclamide
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- King's College Hospital NHS Trust
Pressure Ulcer, Foot Ulcer, Diabetic
Use of Santyl Within an Accountable Care Organization
This study is designed to assess the comparative effectiveness of SANTYL® versus standard of care in the treatment of pressure ulcers and diabetic foot ulcers within the continuum of care of an ACO.
- Trial name
- NCT02716519
- Testing
- Santyl, Standard Care
- Where
- United States
- Sponsor
- Smith & Nephew, Inc.
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Obesity Treatment to Improve Diabetes
As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal…
- Trial name
- OTID (NCT05390307)
- Testing
- Liraglutide / Semaglutide, Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin
- Where
- Kuwait
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Islet Transplantation
Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with…
- Trial name
- NCT05973734
- Testing
- Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived Vertebral Bone Marrow
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Stanford University
Diabetes, Type 1 Diabetes
Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults
In this study the investigators will compare a novel approach using daily financial incentives and a tiered sponsor network to motivate adolescents and young adults with type 1 diabetes to improve glycemic control.
- Trial name
- NCT02568501
- Testing
- Daily feedback, Financial incentive
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Type 1 Diabetes
Autoantibodies in Patients With Type 1 Diabetes Mellitus
Evaluate the autoantibodies, such as glutamic acid decarboxylase (GAD65), tyrosine phosphatase (IA-2 or ICA125), islet autoantibodies (IAA) and other associated autoimmune autoantibodies: microsomal antibodies, thyroglobulin…
- Trial name
- NCT00173628
- Testing
- blood drawing
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Type 1 Diabetes
Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes
This early feasibility first-in-human study is a prospective single-arm single-center study of Sigi insulin patch pump. After a 1st day and night under medical surveillance during a hotel stay, Sigi system will be evaluated…
- Trial name
- SigiFIH (NCT05973422)
- Testing
- SIGI Insulin Management System
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes
Study of Offspring of Women With Type 1 Diabetes
There is an increasing trend in the society for developing obesity, type 2 diabetes and cardiovascular diseases. It is therefore important to identify the risk factors behind this tendency.
- Trial name
- EPICOM (NCT01559181)
- Where
- 3 sites in Denmark
- Volunteers
- 584 people
- Sponsor
- Odense University Hospital
Diabetes Mellitus Type 1
A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes
This crossover, glucose-clamp study will investigate the impact of different basal insulin infusion rates on glucose control employing insulin pumps with different insulin delivery regimen.
- Trial name
- NCT00772356
- Testing
- Accu-Chek Spirit Insulin Pump, Comparator insulin pump
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Basal Insulin And Compensation Glycemic In Diabetic Patients In Basal Bolus Outpatient.
Multicentric, observational, cross-sectional study in Italy. The aims are to evaluate the basal/total ratio of daily insulin dose (b/T) in diabetic outpatients type 1 (T1) and type 2 (T2) on basal-bolus regimen, by investigating…
- Trial name
- BASAL (NCT03489031)
- Volunteers
- 1,036 people
- Sponsor
- Associazione Medici Endocrinologi
Type 1 Diabetes
Assessment of a Decision Support Tool in Participants With Type 1 Diabetes
Type 1 diabetes (T1D) is a complex disease with a high risk of both hyper- and hypoglycemia which can lead to severe acute and chronic complications.
- Trial name
- NCT04428645
- Testing
- DailyDose Decision Support
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes
This trial was conducted in Europe, Middle East, North America and South America. The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®)…
- Trial name
- NCT00365170
- Testing
- human insulin, insulin aspart
- Where
- 95 sites in Argentina, Austria and 16 more
- Volunteers
- 419 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.